Novartis announces expiration of Tourmaline Bio tender offer

Core Points - Novartis announced the expiration of its tender offer to acquire Tourmaline Bio, Inc. at a price of $48.00 per share, which ended on October 27, 2025 [1][2] - Approximately 24,030,382 shares were validly tendered, representing about 92.94% of the outstanding shares prior to the expiration [2] Company Information - Novartis is an innovative medicines company focused on improving and extending lives through its products, reaching over 300 million people globally [5]